The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
The Two-Faced Cytokine IL-6 in Host Defense and Diseases
Open accessAbstract
Interleukein-6 (IL-6), is produced locally from infectious or injured lesions and is delivered to the whole body via the blood stream, promptly activating the host defense system to perform diverse functions. However, excessive or sustained production of IL-6 is involved in various diseases. In diseases, the IL-6 inhibitory strategy begins with the development of the anti-IL-6 receptor antibody, tocilizumab (TCZ). This antibody has shown remarkable effects on Castleman disease, rheumatoid arthritis and juvenile idiopathic arthritis. In 2017, TCZ was proven to work effectively against giant cell arteritis, Takayasu arteritis and cytokine releasing syndrome, initiating a new era for the treatment of these diseases. In this study, the defensive functions of IL-6 and various pathological conditions are compared. Further, the diseases of which TCZ has been approved for treatment are summarized, the updated results of increasing off-label use of TCZ for various diseases are reviewed and the conditions for which IL-6 inhibition might have a beneficial role are discussed. Given the involvement of IL-6 in many pathologies, the diseases that can be improved by IL-6 inhibition will expand. However, the important role of IL-6 in host defense should always be kept in mind in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bettelli, E., Carrier, Y., Gao, W., Korn, T., Strom, T. B., Oukka, M., Weiner, H. L., & Kuchroo, V. K. (2006) · Nature · doi:10.1038/nature04753 · Cited by 6,992 · cited 1×
“The resulting up-regulation of the Th17/Treg balance is thought to be involved in the development of various autoimmune disorders and chronic inflammation [69,70].”
BackgroundKorn, T., Bettelli, E., Oukka, M., & Kuchroo, V. K. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132710 · Cited by 4,873
A Meta-Analysis of Cytokines in Major Depression
Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.09.033 · Cited by 4,729
The role of inflammation in depression: from evolutionary imperative to modern treatment target
Miller, A. H., & Raison, C. L. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2015.5 · Cited by 3,942 · cited 1×
“There is a hypothesis that persistent depressive symptoms are based on host defense [93].”
BackgroundNF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“IL-6 indirectly controls erythropoiesis by stimulating the liver to release hepcidin [57].”
BackgroundIL-6 as a keystone cytokine in health and disease
Hunter, C. A., & Jones, S. A. (2015) · Nature Immunology · doi:10.1038/ni.3153 · Cited by 2,511 · cited 1×
“IL-6 binds with high affinity to cells expressing both membrane IL-6R and gp130, such as hepatocytes, neutrophils, monocytes, activated B cells and CD4 T cells [2].”
BackgroundRidker, P. M., Rifai, N., Stampfer, M. J., & Hennekens, C. H. (2000) · Circulation · doi:10.1161/01.cir.101.15.1767 · Cited by 2,429 · cited 2×
“Evidence has also shown that high levels of IL-6 are associated with cardiovascular disease risk [87,88].”
BackgroundLiang, S. C., Tan, X.-Y., Luxenberg, D. P., Karim, R., Dunussi-Joannopoulos, K., Collins, M., & Fouser, L. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061308 · Cited by 2,330
Fishman, D., Faulds, G., Jeffery, R., Mohamed-Ali, V, Yudkin, J. S., Humphries, S., & Woo, P. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2629 · Cited by 2,243
Black, S., Kushner, I., & Samols, D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.r400025200 · Cited by 1,844
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768 · cited 1×
“In vitro, hepatocytes respond with the other IL-6 family cytokines to produce acute phase proteins; however, it has been shown that IL-6 deficient mice have a severely impaired acute phase response [39].”
BackgroundSelf-citationRaison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 1×
“A double-blind, placebo-controlled, randomized trial with anti-TNFα Ab infliximab in 60 patients with major depression showed an association between baseline levels of the inflammatory marker CRP and the response to infliximab [140].”
BackgroundLiver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice
Cressman, D. E., Greenbaum, L. E., DeAngelis, R. A., Ciliberto, G., Furth, E. E., Poli, V., & Taub, R. (1996) · Science · doi:10.1126/science.274.5291.1379 · Cited by 1,538 · cited 1×
“However, IL-6 treatment rescues these mice by inducing hepatocyte proliferation and preventing liver damage [43].”
Background(2012) · The Lancet · doi:10.1016/s0140-6736(12)60110-x · Cited by 1,146
Update of EULAR recommendations for the treatment of systemic sclerosis
Kowal-Bielecka, O., Fransen, J., Avouac, J., Becker, M., Kulak, A., Allanore, Y., Distler, O., Clements, P., Cutolo, M., Czirjak, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209909 · Cited by 1,104
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040 · cited 1×
“The IL-6/sIL-6R complex activates gp130-expressing cells, even if cells lack membrane IL-6R, a process known as trans-signaling [29].”
BackgroundStahl, N., Farruggella, T. J., Boulton, T. G., Zhong, Z., Darnell, J. E., & Yancopoulos, G. D. (1995) · Science · doi:10.1126/science.7871433 · Cited by 979
IL-6: From its discovery to clinical applications
Kishimoto, T. (2010) · International Immunology · doi:10.1093/intimm/dxq030 · Cited by 846
Self-citation(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation
Kaplanski, G. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(02)00013-3 · Cited by 811
Yokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60454-7 · Cited by 789
Self-citationHumanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Self-citationIL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753 · cited 1×
“On the other hand, the effect of IL-6 on intestinal epithelial cells contributes to the promotion of colon cancer growth, invasion and metastasis [91,92].”
BackgroundInterleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
Kaser, A., Brandacher, G., Steurer, W., Kaser, S., Offner, F. A., Zoller, H., Theurl, I., Widder, W., Molnar, C., Ludwiczek, O., et al. (2001) · Blood · doi:10.1182/blood.v98.9.2720 · Cited by 667 · cited 5×
“IL-6-induced thrombocytosis is abrogated by the neutralization of TPO, suggesting that it is mediated by TPO [54].”
BackgroundInfluentialInterleukin-6: designing specific therapeutics for a complex cytokine
Garbers, C., Heink, S., Korn, T., & Rose-John, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.45 · Cited by 643
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
Choy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526 · cited 1×
“After the promising results of the first randomized controlled trial of TCZ in RA [101], the efficacy of TCZ in RA was demonstrated by many clinical trials [4,102].”
BackgroundSelf-citationInterleukin 6 plays a key role in the development of antigen-induced arthritis
Ohshima, S., Saeki, Y., Mima, T., Sasai, M., Nishioka, K., Nomura, S., Kopf, M., Katada, Y., Tanaka, T., Suemura, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.8222 · Cited by 406 · cited 1×
“Further, IL-6 deficient mice have been reported to still produce antigen-specific Abs in vivo, despite the reduction of levels to less than half of those found in wild type mice [65].”
BackgroundSelf-citationMino, T., Murakawa, Y., Fukao, A., Vandenbon, A., Wessels, H.-H., Ori, D., Uehata, T., Tartey, S., Akira, S., Suzuki, Y., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.029 · Cited by 390
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331
Interleukin-6 Stimulates Defective Angiogenesis
Gopinathan, G., Milagre, C., Pearce, O. M. T., Reynolds, L. E., Hodivala-Dilke, K., Leinster, D. A., Zhong, H., Hollingsworth, R. E., Thompson, R., Whiteford, J. R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1227 · Cited by 249
Regulation of IL-6 in Immunity and Diseases
Tanaka, T., Narazaki, M., Masuda, K., & Kishimoto, T. (2016) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-024-0921-5_4 · Cited by 235
Self-citationArid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo
Masuda, K., Ripley, B., Nishimura, R., Mino, T., Takeuchi, O., Shioi, G., Kiyonari, H., & Kishimoto, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307419110 · Cited by 226
Self-citationHepcidin and Host Defense against Infectious Diseases
Michels, K., Nemeth, E., Ganz, T., & Mehrad, B. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004998 · Cited by 205 · cited 1×
“A reduction in plasma iron is thought to be a defense mechanism against extracellular infections by inhibiting iron availability to invading pathogens [58], whereas sustained elevation of hepcidin by chronic inflammation results in anemia due to the lack of iron availability for erythropoiesis.”
BackgroundGarbers, C., Jänner, N., Chalaris, A., Moss, M. L., Floss, D. M., Meyer, D., Koch-Nolte, F., Rose-John, S., & Scheller, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229393 · Cited by 201
Devauchelle-Pensec, V., Berthelot, J. M., Cornec, D., Renaudineau, Y., Marhadour, T., Jousse-Joulin, S., Querellou, S., Garrigues, F., De Bandt, M., Gouillou, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208742 · Cited by 171
Barkhausen, T., Tschernig, T., Rosenstiel, P., van Griensven, M., Vonberg, R.-P., Dorsch, M., Mueller-Heine, A., Chalaris, A., Scheller, J., Rose-John, S., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318211ff56 · Cited by 169
Distinct Effects of IL-6 Classic and Trans -Signaling in Bone Fracture Healing
Prystaz, K., Kaiser, K., Kovtun, A., Haffner-Luntzer, M., Fischer, V., Rapp, A. E., Liedert, A., Strauss, G., Waetzig, G. H., Rose-John, S., et al. (2018) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.10.011 · Cited by 142
Sun, Y., Wang, D., Salvadore, G., Hsu, B., Curran, M., Casper, C., Vermeulen, J., Kent, J. M., Singh, J., Drevets, W. C., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.06.014 · Cited by 100
Naseem, S., Hussain, T., & Manzoor, S. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.01.002 · Cited by 72 · cited 1×
“In addition to the induction of acute phase proteins, IL-6 is also involved in liver regeneration and liver-mediated adaptive immunity [42].”
BackgroundHou, H., Wang, C., Sun, F., Zhao, L., Dun, A., & Sun, Z. (2015) · Inflammation Research · doi:10.1007/s00011-015-0850-9 · Cited by 55 · cited 1×
“A G/C polymorphism at −174 in the human IL-6 flanking region affects the transcriptional level and is associated with inflammatory diseases [7,8].”
Background
Cited by
Pleiotropy and specificity: insights from the interleukin 6 family of cytokines
Murakami, M., Kamimura, D., & Hirano, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.027 · Cited by 533
The Immunobiology of the Interleukin-12 Family: Room for Discovery
Tait Wojno, E. D., Hunter, C. A., & Stumhofer, J. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.011 · Cited by 482
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 375
Self-citationHistorical overview of the interleukin-6 family cytokine
Kang, S., Narazaki, M., Metwally, H., & Kishimoto, T. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190347 · Cited by 360
Self-citationBiomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values
Dhama, K., Latheef, S. K., Dadar, M., Samad, H. A., Munjal, A., Khandia, R., Karthik, K., Tiwari, R., Yatoo, M. I., Bhatt, P., et al. (2019) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00091 · Cited by 321
Metadata
- Authors
- Narazaki, M., & Kishimoto, T.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-09
- Volume
- 19
- Issue
- 11
- Pages
- 3528
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2899757993
- Cited by
- 201
- References
- 44
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.